Validation of obesity‐related diagnosis codes in claims data-Reference-Cited by-同舟云学术

Validation of obesity‐related diagnosis codes in claims data

Published:2021-08-18 Issue:12 Volume:23 Page:2623-2631
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Suissa Karine¹^ORCID,Schneeweiss Sebastian¹,Lin Kueiyu Joshua¹²,Brill Gregory¹,Kim Seoyoung C.¹³,Patorno Elisabetta¹^ORCID

Affiliation:

1. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA

2. Department of Medicine Massachusetts General Hospital and Harvard Medical School Boston Massachusetts USA

3. Division of Rheumatology, Inflammation, and Immunity Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA

Funder

National Institute on Aging

National Institutes of Health

Bristol-Myers Squibb

Boehringer Ingelheim

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14512

Reference21 articles.

1. Clinical Predictors of Disease Progression and Medication Initiation in Untreated Patients With Type 2 Diabetes and A1C Less Than 7%

2. Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity

3. Validation of body mass index (BMI)-related ICD-9-CM and ICD-10-CM administrative diagnosis codes recorded in US claims data

Validity of ICD-10 diagnoses of overweight and obesity in Danish hospitals

5. Validity of a Claims-Based Diagnosis of Obesity Among Medicare Beneficiaries

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bariatric surgery association with risk of recurrent stroke hospitalization among older stroke survivors with obesity: A national inpatient sample study (2016–2019);Obesity Pillars;2024-12

2. Factors associated with receiving an obesity diagnosis and obesity-related treatment for patients with obesity class II and III within a single integrated health system;Preventive Medicine Reports;2024-10

3. Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study;PLOS ONE;2024-08-08

4. Rise in First-Time ERCP for Benign Indications >1 Year After Cholecystectomy Is Associated With Worse Outcomes;Clinical Gastroenterology and Hepatology;2024-08

5. Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes;Journal of Managed Care & Specialty Pharmacy;2024-08